106 related articles for article (PubMed ID: 3168076)
1. Serial serum calcitonin concentrations to evaluate response to therapy of patients with medullary thyroid carcinoma.
Athanassiades P; Piperingos G; Pandos P; Koutras D; Moulopoulos S
Chemioterapia; 1988 Jun; 7(3):195-7. PubMed ID: 3168076
[TBL] [Abstract][Full Text] [Related]
2. The use of octreotide in the treatment of medullary thyroid carcinoma.
Frank-Raue K; Ziegler R; Raue F
Horm Metab Res Suppl; 1993; 27():44-7. PubMed ID: 8330871
[TBL] [Abstract][Full Text] [Related]
3. Intensive chemotherapy for anaplastic thyroid carcinoma: combination of cisplatin, doxorubicin, etoposide and peplomycin with granulocyte granulocyte colony-stimulating factor support. Chemotherapy Committee, The Japanese Society of Thyroid Surgery.
Jpn J Clin Oncol; 1995 Oct; 25(5):203-7. PubMed ID: 7474408
[TBL] [Abstract][Full Text] [Related]
4. Use of somatostatin analog SMS 201-995 in medullary thyroid carcinoma.
Libroia A; Verga U; Di Sacco G; Piolini M; Muratori F
Henry Ford Hosp Med J; 1989; 37(3-4):151-3. PubMed ID: 2576951
[TBL] [Abstract][Full Text] [Related]
5. [Calcitonin determination as a possibility for the evaluation of surgical result in medullary thyroid carcinoma (C-cell carcinoma)].
Horn J; Pfarr B; Ziegler R
Langenbecks Arch Chir; 1975; Suppl():231-4. PubMed ID: 1207235
[TBL] [Abstract][Full Text] [Related]
6. Therapy of stage IV B anaplastic thyroid carcinoma: single institution experience.
Vrbic S; Pejcic I; Vrbic M; Filipovic S
J BUON; 2009; 14(1):41-4. PubMed ID: 19373945
[TBL] [Abstract][Full Text] [Related]
7. Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma.
Asakawa H; Kobayashi T; Komoike Y; Maruyama H; Nakano Y; Tamaki Y; Matsuzawa Y; Monden M
Anticancer Res; 1997; 17(4A):2757-62. PubMed ID: 9252711
[TBL] [Abstract][Full Text] [Related]
8. Effects of short-term subcutaneous administration of SMS 201-995 on calcitonin plasma levels in patients suffering from medullary thyroid carcinoma.
Guliana JM; Guillausseau PJ; Caron J; Siame-Mourot C; Calmettes C; Modigliani E
Horm Metab Res; 1989 Oct; 21(10):584-6. PubMed ID: 2807148
[No Abstract] [Full Text] [Related]
9. Serum calcitonin-lowering effect of magnesium in patients with medullary carcinoma of the thyroid.
Anast C; David L; Winnacker J; Glass R; Baskin W; Brubaker L; Burns T
J Clin Invest; 1975 Dec; 56(6):1615-21. PubMed ID: 1202087
[TBL] [Abstract][Full Text] [Related]
10. Calcitonin as a tumor marker. Use of the radioimmunoassay for calcitonin in the postoperative evaluation of patients with medullary thyroid carcinoma.
Goltzman D; Potts JT; Ridgway RC; Maloof F
N Engl J Med; 1974 May; 290(19):1035-9. PubMed ID: 4207025
[No Abstract] [Full Text] [Related]
11. Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma.
Vainas I; Koussis Ch; Pazaitou-Panayiotou K; Drimonitis A; Chrisoulidou A; Iakovou I; Boudina M; Kaprara A; Maladaki A
J Exp Clin Cancer Res; 2004 Dec; 23(4):549-59. PubMed ID: 15743023
[TBL] [Abstract][Full Text] [Related]
12. [Combination therapy with adriamycin, cisplatin and vindesine in C cell carcinoma of the thyroid].
Scherübl H; Raue F; Ziegler R
Onkologie; 1990 Jun; 13(3):198-202. PubMed ID: 2204006
[TBL] [Abstract][Full Text] [Related]
13. Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results.
Oshita F; Kasai T; Kurata T; Fukuda M; Yamamoto N; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
Jpn J Clin Oncol; 1995 Oct; 25(5):208-12. PubMed ID: 7474409
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy and multimodality treatment in thyroid carcinoma.
Ekman ET; Lundell G; Tennvall J; Wallin G
Otolaryngol Clin North Am; 1990 Jun; 23(3):523-7. PubMed ID: 1694985
[TBL] [Abstract][Full Text] [Related]
15. Failure of medullary carcinoma of the thyroid to respond to doxorubicin therapy.
Husain M; Alsever RN; Lock JP; George WF; Katz FH
Horm Res; 1978; 9(1):22-5. PubMed ID: 618781
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy for medullary cancer of the thyroid. Phase II trials with adriamycin and cis-platinum administered as monochemotherapy].
Droz JP; Rougier P; Goddefroy V; Schlumberger M; Gardet P; Parmentier C
Bull Cancer; 1984; 71(3):195-9. PubMed ID: 6541515
[TBL] [Abstract][Full Text] [Related]
17. Radioactive iodine treatment in medullary thyroid carcinoma.
Faik Erdogan M; Gursoy A; Erdogan G; Kamel N
Nucl Med Commun; 2006 Apr; 27(4):359-62. PubMed ID: 16531922
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic values of the doubling time of serum carcinoembryonic antigen and calcitonin levels in medullary thyroid carcinoma].
Miyauchi A; Onishi T; Matsuzuka F; Hirai K; Kuma K; Takai S; Nakamoto K; Nakamura K; Nanjo S; Maeda M
Gan No Rinsho; 1986 Oct; 32(12):1519-24. PubMed ID: 3783976
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial.
Williams SD; Birch R; Einhorn LH
Cancer Treat Rep; 1986 Mar; 70(3):405-7. PubMed ID: 3955552
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic thyroid cancer and primary thyroid lymphoma: a review of these rare thyroid malignancies.
Green LD; Mack L; Pasieka JL
J Surg Oncol; 2006 Dec; 94(8):725-36. PubMed ID: 17131397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
